Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MEDI7510
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
MEDI7510 is an investigational intramuscular vaccine developed for the prevention of respiratory syncytial virus (RSV) infections in adults and the elderly. It consists of a recombinant RSV F protein antigen (derived from the A2 strain in postfusion configuration and produced in Chinese hamster ovary cells) combined with GLA-SE, a synthetic adjuvant based on glucopyranosyl lipid A formulated in a squalene-based oil-in-water stable emulsion. The GLA component was licensed from Immune Design's GLAAS discovery platform. The vaccine acts as an immunostimulant to enhance immune responses against RSV infection. Clinical development reached phase II before being discontinued[1][5][7].
02
Targets
RSV F (Respiratory syncytial virus fusion protein)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on MEDI7510.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MEDI7510.